Glioblasztóma: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• MGMT 20
• EGFR 14
• IDH 10
• STAT3 3
• TP53 0
• AKT 0
• mTOR 1
• PI3K 1
• PD-1 7
• ERK 0
• PD-L1 5
• STING 0
• YAP 0
• B7-H3 7
• MAPK 0
• PARP 1
• CTNNB1 0
• PTEN 1
• VEGF 5
• AMPK 0
• BRAF 1
• TERT 3
• FGFR 1
• PRMT5 5
• CDK4/6 0
• HDAC 0
• HIF-1 1
• IL-6 0
• NRF2 0
• PSMA 4
• MYC 2
• COX-2 0
• CXCR4 0
• EZH2 0
• CD47 0
• HER2 2
• JAK 0
• MEK 0
• MET 1
• METTL3 0
• TLR4 0
• ATM 2
• GPX4 0
• MDM2 0
• BCL-2 0
• CDKN2A 0
• CTLA-4 0
• FAK 0
• HSP90 0
• JNK 0
• MMP-9 1
• TNF 0
• CD19 0
• NF1 1
• NTRK 1
• TREM2 0
• AR 0
• CD40 1
• HMGB1 0
• IDO1 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of tRNA-dependent translational control in the onset and progression of Glioblastoma. (tRansGlio)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 226 421 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the mechanisms driving cancer cell DORMancy and REcurrence in glioblastoma (DORMIRE)

  Universite de Lausanne· Lausanne, Svájc· EU contribution 292 119 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  ECLIPSE: Unveiling Brain Tumor Metabolism with Advanced In Vivo MRI

  Universitair Medisch Centrum Utrecht· Utrecht, Hollandia· EU contribution 2 099 257 EUR· until 2032. máj.

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma (VideoTranscriptomics)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 1 484 173 EUR· until 2032. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discovery (FutureMIND)

  Ruprecht-Karls-Universitaet Heidelberg· Heidelberg, Németország· EU contribution 4 379 817 EUR· until 2030. dec.· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 4 366 500 EUR· until 2030. dec.· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Safeguard Repressor-Mediated Cell Fate Lock Gene Therapy for Glioblastoma (SafeCure)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 150 000 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-ERC

  Modeling oncogenesis, phenotypic identity and fate in brain cancer avatars (MOIRA)

  Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (Mdc)· Berlin, Németország· EU contribution 2 487 500 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Magnetopyroelectric Biomedical Microrobots (PYROBOTS)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Svájc· EU contribution 2 490 692 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the transcriptional and evolutionary maps of diffuse midline glioma to overcome treatment resistance (RESET-DMG)

  Uppsala Universitet· Uppsala, Svédország· EU contribution 1 449 469 EUR· until 2031. nov.

10 of 821 running projects, newest first. Listed amounts together: 179,2 M EUR + 403,5 M USD.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 11
• Gene Expression Profiling 151
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 226
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 234
• Machine Learning 266
• Deep Learning 43
• Cohort Studies 54
• Genome-Wide Association Study 13

• Temporally evolving neuronal remodeling via the CTNNB1-NRG3-ERBB4 axis drives therapy resistance in glioblastoma.

  Mol Biomed, 2026. nov.

• Target proteomics-based analysis of the deep association between USP30 and prognosis of glioblastoma multiforme.

  Int J Surg, 2026. nov.

• Familial Glioma in a Father and Son: Integrated Genomic and Multi-compartment Proteomic Profiling.

  Anticancer Res, 2026. nov.

• Longitudinal plasma protein profiling in glioblastoma patients using NULISAseq reveals treatment-associated changes across radiation and chemotherapy.

  J Neurooncol, 2026. okt.

• Advances in Single-Cell and Spatial Omics for Glioblastoma Precision Medicine.

  Curr Oncol Rep, 2026. okt.

• Spatial heterogeneity in glioblastoma: linking single-cell and spatial multi-omics to vaccine immunotherapy.

  Front Immunol, 2026. okt.

• Molecular and Proteomic Profiling of Human Cerebral Organoid‑Derived Small Extracellular Vesicles.

  Dev Neurobiol, 2026. okt.

• Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization.

  Acta Neuropathol, 2026. szept.

• Spatial analysis reveals the evolving organization of IDH-mutant glioma.

  Cancer Cell, 2026. szept.

• Identification of Glioblastoma Cell Surface Proteins and Assessment of Their Expression Across Patient-Derived Stem-Like Cell Cultures.

  J Proteome Res, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.